Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2026-02-25 @ 7:04 PM
Study NCT ID:
NCT02870569
Status:
COMPLETED
Last Update Posted:
2019-03-01
First Post:
2016-08-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer
Sponsor:
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
RG01N-1271
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None